Founded in 1994
Financial data: €275M Market Cap (on 13/02/2017)
Medigene concentrates on the development of personalized T cell immunotherapies, with focus on haematological malignancies.
Lochhamer Str. 11
Exclusive from BIO-Europe 2015: Interview of Peter Llewellyn-Davies, CFO at Medigene, Munich-based Immunotherapy Biotech
Deals & Finance
Medigene plans to fund its T-cell program with €50 Millions
Biotech of the Week
This French Biotech Wants to Reinvent DC-based Immunotherapies
Which EU Immuno-Oncology Company are you Cheering for?
Labiotech UG, All Rights Reserved -
Send this to friend